NCT06683612 - PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

June 4, 2025

Study Completion Date

June 12, 2025

Conditions

Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisMultiple SclerosisMultiple Sclerosis, MSMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, ProgressiveMultiple Sclerosis, Secondary ProgressiveHealthyHealthy Volunteers

Interventions

DRUG

PIPE-791

Subjects will receive a single oral dose of PIPE-791.

Trial Locations (1)

Unknown

Hammersmith Medicines Research, London